The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group has signed a three-year deal with Australian private healthcare provider Healthscope for $895,000
  • The three-year deal will see the companies work together to support Healthscope’s vision for using data to drive transformation
  • Alcidion will develop dashboards to support predictive analytics and long-range planning

Alcidion Group has signed a three-year deal with Australian private healthcare provider Healthscope for $895,000.

Healthscope is a leading private healthcare provider with 43 private hospitals in Australia and New Zealand. It has a team of 18,000 people and 17,500 accredited medical practitioners.

Alcidion aims to transform healthcare with smart and initiative technology solutions that meet the needs of hospital and allied healthcare worldwide.

The company offers a complementary set of software products and services that create a unique offering in the global healthcare market.

The three-year deal will see the companies work together to support Healthscope’s vision for using data to drive transformation in the way healthcare is managed and delivered.

Using data from Healthscope’s hospitals, Alcidion will develop dashboards to support predictive analytics and long-range planning for Healthscope services.

Alcidion Managing Director Kate Quirke is excited to establish a relationship with Healthscope to increase the data and analytic capabilities across the organisation.

“This is Alcidion’s first implementation of our data analytics capabilities into a private hospital group. It demonstrates how important data is becoming across the healthcare sector,” she said.

Alcidion technology is implemented in over 215 hospitals across Australia, the U.K. and New Zealand and is currently working with over 42 healthcare organisations.

“We look forward to sharing our extensive capabilities around health care data management to assist Healthscope to drive better outcomes,” Kate added.

Alcidion Group has gained 13.1 per cent on the ASX today and is currently selling shares for 23 cents apiece at 12:58 pm AEST.

ALC by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…